Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Nghia Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 937-949.e2
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease
Sonika Sethi, Shiluka Dias, Aditi Kumar, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 12, pp. 1362-1374
Open Access | Times Cited: 43
Inflammatory bowel disease: recent developments
James J. Ashton, R. Mark Beattie
Archives of Disease in Childhood (2023) Vol. 109, Iss. 5, pp. 370-376
Open Access | Times Cited: 25
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Effect of huankuile on colon injury in rats with ulcerative colitis by reducing TNF-α and MMP9
Xilinguli Wushouer, Kasimujiang Aximujiang, Nafeisha Kadeer, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 4
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients
Andrea Pascual-Oliver, Diego Casas Deza, Camila Cuarán, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 6, pp. 922-929
Closed Access | Times Cited: 11
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 171-189
Closed Access | Times Cited: 3
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease
Rachel Porth, Tina Deyhim, Grace Geeganage, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
Ferdinando D’Amico, Virginia Solitano, Fernando Magro, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6350-6350
Open Access | Times Cited: 8
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study
Cynthia H. Seow, John K. Marshall, Erin Stewart, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 7, Iss. 4, pp. 290-298
Open Access | Times Cited: 2
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST
Laurent Peyrin‐Biroulet, Séverine Vermeire, Geert R. D’Haens, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 2, pp. 175-185
Open Access | Times Cited: 7
Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
А. И. Хавкин, A. V. Nalyotov, Н. А. Марченко
Russian Journal of Gastroenterology Hepatology Coloproctology (2023) Vol. 33, Iss. 6, pp. 7-15
Open Access | Times Cited: 7
Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring
Devendra Desai, Alpa J. Dherai, Anne S. Strik, et al.
The Journal of Clinical Pharmacology (2022) Vol. 63, Iss. 4, pp. 480-489
Open Access | Times Cited: 11
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review
Zachary Green, R. Mark Beattie, James J. Ashton
Translational Pediatrics (2023) Vol. 12, Iss. 10, pp. 1853-1874
Open Access | Times Cited: 6
De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 642-658
Closed Access | Times Cited: 6
Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
Adriaan Volkers, Mark Löwenberg, Marlou Braad, et al.
Diagnostics (2023) Vol. 13, Iss. 10, pp. 1712-1712
Open Access | Times Cited: 5
Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis
Noemí Manceñido, Blanca Novella Arribas, Gustavo Mora Navarro, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 421-428
Closed Access | Times Cited: 5
The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
The association between drugs and repeated treatment with budesonide in patients with microscopic colitis: a retrospective observational study
Oliver Bjurström, Pontus Karling
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
Ferdinando D’Amico, Virginia Solitano, Fernando Magro, et al.
(2023)
Open Access | Times Cited: 4
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis
Samuel Fernandes, Sónia Bernardo, S Saraiva, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 11, pp. 1974-1982
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top